Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole.

@article{Frankel2017BrexpiprazoleAC,
  title={Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole.},
  author={Joshua S Frankel and Thomas L. Schwartz},
  journal={Therapeutic advances in psychopharmacology},
  year={2017},
  volume={7 1},
  pages={
          29-41
        }
}
BACKGROUND Brexpiprazole and cariprazine are the latest US Food and Drug Administration approved atypical antipsychotics available in the United States. Both function as partial agonists of the dopamine-2 receptor (D2R), a mechanism of action shared with aripiprazole. However, all three differ in their affinities for the D2R as well as for serotonin receptors (5-HTRs). This paper seeks to delineate these pharmacodynamic and clinical differences amongst the three dopamine partial agonist… CONTINUE READING
BETA
4
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

Brexpiprazole: A Review in Schizophrenia

VIEW 8 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

In vitro and in vivo anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety profile

Shuhei Suzuki, Masahiro Yamamoto, +6 authors Masashi Okada
  • Oncotarget
  • 2019
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Dopamine: Functions, Signaling, and Association with Neurological Diseases

  • Cellular and Molecular Neurobiology
  • 2018
VIEW 3 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 50 REFERENCES

Similar Papers

Loading similar papers…